TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:200230)
South Korea · Delayed Price · Currency is KRW 2,725.00
+2,365.00 (656.94%)
Jun 30, 2026, 9:50 AM KST
TELCON RF PHARMACEUTICAL. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 42,878 | 43,162 | 37,865 | 36,307 | 27,830 | 37,841 |
Other Revenue | 0 | - | - | -0 | - | -0 |
| 42,878 | 43,162 | 37,865 | 36,307 | 27,830 | 37,841 | |
Revenue Growth (YoY) | 7.70% | 13.99% | 4.29% | 30.46% | -26.46% | 14.18% |
Cost of Revenue | 32,437 | 33,042 | 27,628 | 26,800 | 22,267 | 28,780 |
Gross Profit | 10,440 | 10,120 | 10,237 | 9,507 | 5,563 | 9,061 |
Selling, General & Admin | 6,105 | 5,978 | 6,252 | 4,484 | 4,554 | 6,949 |
Research & Development | 679.37 | 699.14 | 722.94 | 733.17 | 1,208 | 1,635 |
Amortization of Goodwill & Intangibles | 2,504 | 2,504 | 2,548 | 2,565 | 2,582 | 2,597 |
Other Operating Expenses | 186.43 | 253.11 | 112.54 | 59.76 | 68.03 | 168.3 |
Operating Expenses | 9,645 | 9,401 | 10,307 | 8,542 | 9,626 | 13,624 |
Operating Income | 795 | 718.59 | -70.55 | 965.32 | -4,063 | -4,563 |
Interest Expense | -4,443 | -4,813 | -3,760 | -603.58 | -1,063 | -7,702 |
Interest & Investment Income | 857.68 | 682.02 | 324.97 | 205.05 | 61.42 | 45.48 |
Earnings From Equity Investments | 470.74 | -3,222 | -24,684 | 469.53 | -17,868 | -13,196 |
Currency Exchange Gain (Loss) | 160.59 | -125.74 | 602.71 | 119.08 | 318.02 | 831.71 |
Other Non Operating Income (Expenses) | 2,320 | 2,340 | 1,119 | -837.92 | -1,981 | 77.32 |
EBT Excluding Unusual Items | 160.79 | -4,420 | -26,468 | 317.48 | -24,595 | -24,507 |
Gain (Loss) on Sale of Investments | -7,299 | -5,817 | 1,275 | 13,466 | -13,146 | 4,626 |
Gain (Loss) on Sale of Assets | 34.99 | - | 17.27 | -14.8 | 34.38 | 10.31 |
Asset Writedown | -1,324 | -1,324 | -1,097 | -64.8 | -4,411 | -3,005 |
Other Unusual Items | 130.12 | 130.12 | -227.31 | 244.63 | - | - |
Pretax Income | -8,297 | -11,431 | -26,500 | 13,949 | -42,117 | -22,875 |
Earnings From Continuing Operations | -8,297 | -11,431 | -26,500 | 13,949 | -42,117 | -22,875 |
Earnings From Discontinued Operations | - | - | - | - | - | -331.42 |
Net Income to Company | -8,297 | -11,431 | -26,500 | 13,949 | -42,117 | -23,207 |
Minority Interest in Earnings | -0.92 | -24.35 | 180.11 | -42.34 | 32.81 | 108.8 |
Net Income | -8,298 | -11,456 | -26,320 | 13,906 | -42,084 | -23,098 |
Net Income to Common | -8,298 | -11,456 | -26,320 | 13,906 | -42,084 | -23,098 |
Shares Outstanding (Basic) | 56 | 48 | 35 | 34 | 32 | 26 |
Shares Outstanding (Diluted) | 56 | 48 | 35 | 45 | 41 | 26 |
Shares Change (YoY) | 56.76% | 35.21% | -20.93% | 8.89% | 56.33% | 2.65% |
EPS (Basic) | -147.95 | -238.83 | -741.93 | 414.65 | -1322.39 | -876.43 |
EPS (Diluted) | -148.09 | -239.00 | -742.00 | 341.71 | -1322.39 | -876.43 |
Free Cash Flow | 404.69 | 1,347 | -3,749 | -4,954 | -2,912 | -2,613 |
Free Cash Flow Per Share | 7.21 | 28.08 | -105.68 | -110.43 | -70.69 | -99.13 |
Gross Margin | 24.35% | 23.45% | 27.03% | 26.19% | 19.99% | 23.95% |
Operating Margin | 1.85% | 1.67% | -0.19% | 2.66% | -14.60% | -12.06% |
Profit Margin | -19.35% | -26.54% | -69.51% | 38.30% | -151.22% | -61.04% |
Free Cash Flow Margin | 0.94% | 3.12% | -9.90% | -13.64% | -10.46% | -6.90% |
EBITDA | 5,688 | 5,543 | 4,436 | 5,210 | 218.47 | -363.07 |
EBITDA Margin | 13.27% | 12.84% | 11.72% | 14.35% | 0.78% | -0.96% |
D&A For EBITDA | 4,893 | 4,824 | 4,507 | 4,244 | 4,281 | 4,200 |
EBIT | 795 | 718.59 | -70.55 | 965.32 | -4,063 | -4,563 |
EBIT Margin | 1.85% | 1.67% | -0.19% | 2.66% | -14.60% | -12.06% |
Advertising Expenses | - | 13.19 | 35.06 | 10.77 | 45.18 | 3.36 |